Mirap (Mirtazapine)

Mirtazapine, the active ingredient in Mirap, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and works by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves mood. - Depressive episodes with insomnia: enhances sleep quality while treating depression. - Depressive episodes with anxiety: alleviates anxiety symptoms associated with depression.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Serotonin syndrome when combined with other serotonergic agents - Suicidal thoughts or behavior, especially early in treatment - Abnormal liver function tests

Before initiating therapy, consider the following safety measures.

- Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: avoid unless prescriber determines benefit outweighs potential infant exposure. - Elderly patients: monitor for excessive sedation and increased fall risk. - Concomitant MAO inhibitors: avoid due to risk of hypertensive crisis and serotonin syndrome. - History of bipolar disorder: monitor for possible mood switching to mania. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): increased risk of serotonin syndrome. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihypertensive drugs: potential additive hypotensive effect. - Warfarin: monitor INR as mirtazapine may affect coagulation.